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Abstract 
Background: Dormant disseminated tumour cells can be detected in the bone marrow of 
breast cancer patients several years after resection of the primary tumour. The majority of 
these patients will remain asymptomatic, however, ~15% will go on to develop overt bone 
metastases and this condition is currently incurable. The reason why these dormant cells are 
stimulated to proliferate and form bone tumours in some patients and not others remains to 
be elucidated. We have recently shown that in an in vivo model, increasing bone turnover by 
ovariectomy stimulated proliferation of disseminated tumour cells, resulting in formation of 
bone metastasis. We now show for the first time that osteoclast mediated mechanisms 
induce growth of tumours from dormant MDA-MB-231 cells disseminated in the bone. We 
also show that disruption of RANK-RANKL interactions following administration of OPG-Fc 
inhibits growth of these dormant tumour cells in vivo. Our data support early intervention 
with anti-resorptive therapy in a low-oestrogen environment to prevent development of 
bone metastases. 
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Introduction 
Metastatic breast cancer remains a considerable clinical challenge, causing around 
12,000 deaths annually in the UK alone. The majority of patients with advanced disease will 
develop bone metastases, in many cases several years after removal of the primary tumour. 
It is increasingly accepted that, in breast cancer, the dissemination of tumour cells from the 
primary site to specific niches in the bone marrow is an early event, completed prior to 
diagnosis and initiation of therapy. Tumour cells can remain dormant in the bone marrow 
for decades and may never proliferate to form overt bone metastases. The precise cellular 
and molecular mechanisms that regulate tumour cell dormancy in bone, and the signals that 
trigger tumour cell escape from dormancy, remain to be established. However, the tumour 
microenvironment is suggested to play a major role in both processes, and therefore 
represents a key therapeutic target (1-2).  
Development and progression of breast cancer bone metastases has been intensely 
studied, demonstrating that the process is driven by close interactions between tumour cells 
and components of the bone microenvironment. In particular, tumour cell-mediated 
stimulation of the bone-resorbing osteoclasts is shown to be responsible for the lytic bone 
lesions associated with late stage disease (3). In contrast, our understanding of the early 
stages of tumour cell dissemination to the skeleton, as well as the initiation of tumour cell 
growth, is less clearly defined. Both osteoblasts and osteoclasts, as well as components of 
the extracellular matrix, are proposed to play a role in the early stages of bone metastasis 
(reviewed in: 3,4).  
Due to the key role of the bone microenvironment, treatment of overt bone 
metastases involves a combination of agents that target tumour cells directly as well as 
bone-targeted agents like bisphosphonates and denosumab (5,6). However, whether 
adjuvant targeting of the bone microenvironment (in particular the osteoclast) can reduce 
bone metastasis remains controversial. The recently published AZURE trial found that 
treating breast cancer patients considered at high risk of developing bone metastases with 
Zoledronic acid was only beneficial in patients with established menopause (7). This 
surprising result has been confirmed in other clinical trials, but the underlying mechanisms 
are yet to be identified. Adjuvant trials of denosumab are ongoing (D-CARE), and will provide 
further information as to whether osteoclast-mediated processes are key to the differential 
effects on breast cancer bone metastasis according to menopausal status. 
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One of the main unanswered questions in relation to initiation of bone metastasis is 
how changes to the bone microenvironment, including accelerated bone turnover, affects 
disseminated tumour cells in bone. Recent advances in technology have facilitated the 
studies of individual tumour cells within their resident bone niches. We and others have 
used a combination of in vivo bone metastasis models and advanced imaging to investigate 
how bone-targeted agents modify the bone microenvironment and how this affects 
subsequent tumour cell homing/proliferation (8-12,). Using this approach, we recently 
demonstrated that accelerated bone turnover caused by ovariectomy (OVX) resulted in 
proliferation of disseminated tumour cells and increased levels of bone metastases (8). 
Tumour growth in bone was inhibited by the anti-resorptive agent zoledronic acid, 
suggesting that osteoclast activity is involved in regulating early stages of bone metastasis, 
as well as in end stage disease.  If this hypothesis is correct, other anti-resorptive agents 
working through different mechanisms should also prevent both OVX-induced bone loss and 
growth of dormant tumour cells in bone. The agent of choice to investigate this is 
denosumab, a monoclonal antibody that binds human receptor activator of nuclear factor 
(NF)-kB ligand (RANKL) with high affinity, thereby blocking RANK-RANKL interactions 
essential for osteoclastogenesis. Denosumab is shown to be superior to zoledronic acid for 
the prevention or delay of skeletal complications in patients with advanced cancer and bone 
metastases (13). However, denosumab is human specific and cannot be used in murine in 
vivo models. Instead we have used OPG-Fc, a potent inhibitor osteoclastogenesis that acts 
by preventing RANKL-RANK binding and hence modifies the same pathways as denosumab 
(14). We investigated the effects of inhibiting OVX-induced bone resorption through 
targeting RANKL-RANK interactions in an in vivo model of disseminated breast cancer cells in 
bone.  
The current study is the first to demonstrate that administration of OPG-Fc inhibits 
OVX-induced growth of disseminated, dormant, tumour cells in bone in vivo. Our data 
support the early administration of anti-resorptive therapy in a low-oestrogen setting to 
prevent development of bone metastases. 
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Materials and methods 
Cell Culture: Low passage (< P10) human MDA-MB-231 breast cancer cells transfected with 
the red fluorescent protein, TdTomato (RFP) and second generation luciferase (luc-2) 
(Calliper Life Sciences, Manchester, UK) were cultured in DMEM + 10% FCS (Gibco®, 
Invitrogen, Paisley, UK). Prior to injection, tumour cells were incubated for 15 minutes with 
25µM of 1,1′-Dioctadecyl-′, 3′-Tetramethylindodicarbocyanine, 4-Chlorobenzenesulfonate 
(DiD) (Life Technologies, Paisley, UK). DiD is a lipophilic membrane dye that becomes diluted 
each time the cell divides enabling visualisation of non-proliferating, disseminated tumour 
cells in bone by 2-photon microscopy. Tumour growth was monitored using an IVIS Lumina II 
system (Calliper Life Sciences).  
 
In vitro experiments: For cell proliferation experiments, 1x10
4
 MDA-MB-231 cells were 
seeded in 2mls of DMEM + 0, 2.5, 5, 7.5 or 10% FCS in 12 well tissue culture plates (Corning, 
Paisley, UK). 24h after seeding cells were treated with 0, 10, 50 or 100μg/ml recombinant 
OPG (OPG-Fc) (comprising amino acids 22-194 of human OPG fused at the N-terminus of the 
Fc domain of human immunoglobulin G1 (15). This compound is certified as endotoxin free 
and was a kind gift from Amgen). Cells were harvested using trypsin/EDTA (SigmaAldrich, 
Poole, UK) at 24, 48, 72 and 144h and numbers of tumour cells were counted using a 
hemacytometer. For clonogenic assays 1000 or 500 cells were seeded into 6-well tissue 
culture plates containing saline / 100µg/ml OPG-Fc in 2mls DMEM or into 2mls of DMEM 
and left for 24h before addition of OPG-Fc. All experiments were carried out three times in 
triplicate 
 
 In vivo studies: We used 12-week-old female BALB/c nude mice (Charles River, Kent, UK). 
Experiments were carried out in accordance with local guidelines and with Home Office 
approval under project licence 40/3462, University of Sheffield, UK. 
To investigate the effects of ovariectomy on dormant tumour cells in bone, 1x10
5
 MDA-MB-
231 cells were injected into the left cardiac ventricle of 19 mice. Mice were ovariectomised 
or sham ovariectomised (n=7/group) 56 days after tumour cell injection and culled 28 days 
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later. In addition, 5 mice were culled on day 56 and analysed for presence of disseminated 
tumour cells in the long bones.  
Effects of OPG-Fc on bones were analysed 4 weeks following weekly intra-venous injection 
(i.v) of 25mg/kg OPG-Fc. Effects of OPG-Fc on ovariectomy-induced tumour growth were 
investigated in mice injected into the left cardiac ventricle with 1x10
5
 DiD labelled MDA-MB-
231 cells on day 0. On day 5 mice were given weekly OPG-Fc (25mg/kg i.v) or saline 
(n=20/group) and on day 7, animals from both groups underwent either sham or 
ovariectomy (n=7/group).  
Whole blood was collected by cardiac puncture and the isolated serum was stored at -80
0
C 
for ELISA, tibiae and femurs were fixed in 4% PFA for µCT analysis before decalcification in 
1%PFA/0.5% EDTA and processing for histology. Bones for two-photon analysis were stored 
in OCT at -80
0
C.  
 
Microcomputed tomography imaging: Microcomputed tomography analysis was carried out 
using a Skyscan 1172 x-ray-computed microtomography scanner (Skyscan, Aartselaar, 
Belgium) equipped with an x-ray tube (voltage, 49kV; current, 200uA) and a 0.5-mm 
aluminium filter was used. Pixel size was set to 5.86 µm and scanning initiated from the top 
of the proximal tibia as previously described (16). 
 
Bone histology: Histological sections (5μM) of decalcified tibiae (5μmol/L EDTA fro 4 weeks) 
were stained with Goldner’s trichrome or Safranin O using standard protocols. Osteoclasts 
were detected by tartrate-resistant acid phosphatase (TRAP) staining and osteoblasts were 
identified as mononuclear, cuboidal cells residing in chains along the bone surface as 
previously described (17).   
 
Two-photon microscopy: Detection of individual tumour cells disseminated into mouse 
tibiae in which no tumour growth was observed by luciferase imaging was carried out by 
two-photon microscopy. Dissected tibias were snap frozen in liquid nitrogen, embedded in 
CryoMBed embedding medium and trimmed longitudinally to expose bone marrow area 
using a cryostat (Bright 126 Instrument Co. Ltd). A stack area of 2104μm (X) x 2525μm (Y) x 
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100μm (Z) incorporating the proximal tibiae was imaged (Zeiss LSM510 NLO microscope Carl 
Zeiss Inl). DiD labelled, non-proliferating, tumour cells were visualised using a 633nm 
Chameleon laser, bone was detected using the 900nm multiphoton laser (Coherent, Santa 
Clara, CA.) and images were reconstructed in LSM software version 4.2 (Zeiss). 
 
Biochemical analysis: Serum concentrations of TRAP 5b and P1NP were measured using 
commercially available ELISA kits: MouseTRAP™ Assay (Immunodiagnostic systems) and 
Rat/Mouse P1NP competitive immunoassay kit (Immunodiagnostic Systems), respectively. 
 
Statistical Analysis: Statistical analysis was by one way analysis of variance (ANOVA) 
followed by Newman-Keuls multiple comparison test. Statistical significance was defined as 
P less than or equal to 0.01.  All P values are two-sided. 
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Results 
Effects of ovariectomy on growth of dormant breast cancer cells in bone  
We have previously shown that ovariectomy (OVX) increases bone turnover in 12-week old 
mice and that performing OVX, either 7 days before or 7 days after intra-cardiac (i.c.) 
injection of breast cancer cells, results in significantly increased bone metastasis (8). To 
more closely mimic the clinical situation, where disseminated tumour cells lie dormant in 
bone for prolonged periods, we have now investigated whether OVX also induces growth of 
tumour cells that have remained non-proliferative in bone for 8 weeks. BALB/c nude mice 
were injected i.c. with MDA-MB-231 cells on day 0 and monitored by weekly in vivo imaging.  
If animals had not developed long bone metastases by day 56, the disseminated tumour 
cells in bone were considered to be dormant. Animals without long bone tumours 
underwent either OVX (n=7) or sham operation (n=7) on day 56. A cohort of animals was 
culled to confirm the presence of dormant disseminated tumour cells in long bones (n=5) 
(figure 1a). 
As expected, OVX stimulated tumour growth in the long bones, with bone metastases 
detected in 6/7 mice 4 weeks later (figure 1b). In contrast, no metastases were seen in the 
long bones of sham operated animals. Tumour growth at other sites, including spine, ribs 
and head, were comparable in both experimental groups and was unaltered by ovariectomy 
(figure 1c). Analysis of tibiae 56 days following tumour cell injection confirmed the presence 
of non-proliferating (dormant) DiD-labelled cells in close proximity to trabecular bone (figure 
1d). DiD-labelled tumour cells were detected in the tibia of all mice, including those that did 
not develop tumours by the end of the experimental protocol (day 84). μCT analysis of 
proximal tibiae from OVX and sham operated mice confirmed that OVX significantly reduced 
trabecular bone volume compared with tissue volume P <0.01 (figure 1 e). 
These data demonstrate that tumour cells can remain dormant in bone for prolonged 
periods of time in vivo, and that altering the bone microenvironment through OVX triggers 
their proliferation and development into overt bone metastases. 
 
Effects of OPG-Fc on the bone microenvironment 
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We next investigated whether the OVX-induced changes to the bone microenvironment 
could be counteracted by inhibition of bone turnover. Osteoprotegerin (OPG) inhibits 
osteoclastogenesis through disrupting RANKL-RANK interactions (14). We established the 
effects of weekly administration of 25mg/kg OPG-Fc on the bone microenvironment in our 
model system. As shown in figure 2, animals receiving OPG-Fc displayed increased bone 
volume, had an extended growth plate and reduced serum levels of markers of both 
osteoclast (TRAP) and osteoblast (P1NP) activity, compared to the control group. This was 
accompanied by striking reductions in the numbers of osteoblasts and osteoclasts (figure 2a). 
Scoring of histological sections revealed 3.22 ± 1.46 osteoclasts and 98.16 ± 17.42 
osteoblasts per mm of bone surface in tibiae of control mice, whereas both cell types were 
undetectable on endocortical and trabecular surfaces of tibiae 4 weeks following weekly 
injection of 25mg/kg OPG-Fc. The most dramatic change was seen in the bone volume, with 
the percentage of bone volume compared with tissue volume increasing from 8.19 ± 0.29% 
in control animals to 23.55 ± 0.21% in animals receiving OPG-Fc, p < 0.001. This change was 
mainly due to the extended growth plate and increased proteoglycan rich matrix in the 
metaphysis of bones from OPG-Fc treated compared with control mice (figure 2a). The 
increase in bone volume may, therefore, be a result of elevated ossification due OPG-Fc 
induced disruption of osteoclast activity preventing resorption of this access matrix.  
 
OPG-Fc inhibits OVX-induced growth of disseminated tumour cells 
Having established that OPG-Fc has no direct effects on the ability of MDA-MB-231 cells to 
form colonies or proliferate in vitro (Figure 3) we investigated its effects on growth of 
disseminated, dormant, tumour cells in the long bones. MDA-MB-231 cells were injected i.c. 
in 12-week old BALB/c nude mice that were treated once weekly with either saline (n=14) or 
25mg/kg OPG-Fc (n=14) from day 4. Half of the animals in each group underwent either OVX 
or a sham operation on day 7 (see outline in Figure 4a). As expected, 78.5% of the animals in 
the OVX/saline group developed long bone tumours by day 35, compared to only 14.5% of 
the animals in the sham/saline group (Figure 4b,c). Administration of OPG-Fc completely 
prevented OVX-induced tumour growth, with 7% animals in the OVX/OPG-Fc group having 
detectable long bone tumours, compared to 78.5% in the OVX/saline group. Tumour 
frequency in sham-operated animals was unaffected by OPG-Fc (7.5% of animals having 
detectable bone metastases in sham/OPG-Fc vs 14.5% in sham/saline). In addition, in the 
small number of animals in which tumours did grow in the bone OPG-Fc significantly 
Page 9 of 24
John Wiley & Sons, Inc.
International Journal of Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 10
reduced tumour size in both OVX (P < 0.01) and sham OVX (P < 0.01) operated mice. 
Luciferase imaging showed no effect of OPG-Fc on tumour grown outside of bone (figure 4d) 
This is the first demonstration that administration of OPG-Fc has profound inhibitory effects 
on disseminated tumour cells in vivo, preventing development of overt bone metastases. 
 
OPG-Fc prevents OVX-induced changes to the bone microenvironment 
In order to confirm that administration of OPG-Fc reversed OVX-induced bone loss, we 
carried out a detailed characterisation of the tibia of the animals in the tumour study 
described in the previous section. As shown in figure 5 a and b, OPG-Fc caused a highly 
significant increase in bone volume compared to saline control in both the OVX and sham 
group (percentage of bone volume compared with tissue volume is 11.49 ± 0.51% in saline 
treated sham operated mice compared with 24.73 ± 1.64% in OPG-Fc treated sham mice 
(P<0.001) and 7.86 ± 0.44% in saline treated OVX mice compared with 23.98 ± 3.22% in OPG-
Fc treated OVX mice (P<0.001)). The increased bone volume was accompanied by a 
corresponding decrease in serum TRAP and P1NP levels (P<0.001 for sham saline vs. sham 
OPG-Fc and P<0.001 for OVX saline vs. OPG-Fc for both TRAP and P1NP) (figure 5 c and d), 
confirming that OPG-Fc counteracts OVX-induced bone loss in the animals where growth of 
disseminated tumour cells was inhibited.  
 
Discussion 
In the current study we have used mouse models of MDA-MB-231 breast cancer cell 
dormancy in bone and advanced in vivo imaging to investigate the effects of OVX induced 
stimulation of osteoclastic bone resorption on the formation of metastases. In addition, we 
have studied the effects of targeting RANKL-RANK interactions with OPG-Fc on the 
formation and progression of OVX-induced bone metastases.  
We have previously reported that OVX performed 7 days after tumour cell injection of MDA-
MB-231 breast cancer cells (i.c) leads to increased bone metastases in 12-week old balb/c 
mice (8).  This result was confirmed in the current study (figure 4). However, our previous 
studies did not investigate whether this model reflected the clinical situation, in which bone 
metastases are thought to form from dormant tumour cells. In breast cancer patients it is 
generally accepted that tumour cells are disseminated in the bone marrow in the early 
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stages of disease, often before diagnosis, and that these cells remain dormant unless 
triggered to proliferate as a result of changes in their microenvironment (4-5). In the current 
study we show that once MDA-MB-231 tumour cells are disseminated in the bones of 12-
week old Balb/c mice (with low bone turnover) these tumour cells remain dormant in this 
environment for the entire 12-week experimental protocol, confirming that our model 
mimics tumour cell dormancy. A decrease in circulating oestrogen following OVX leads to 
changes in the bone microenvironment in both humans and animal models (18-20), These 
changes have the net effect of increasing osteoclastic bone resorption (18-20). Our data 
confirm significant bone loss in mice following OVX. Importantly we also show that altering 
the bone microenvironment by OVX stimulates proliferation of tumour cells that have 
previously been dormant in the bone microenvironment for 8 weeks. OVX stimulation of 
dormant tumour cells was specific to long bones and no effects were seen in other bones or 
soft tissues. MDA-MB-231 cells primarily home to long bones following i.c. injection in mice 
(21) and tumour growth at other sites is uncommon. We therefore hypothesise that lack of 
detectable tumour growth by luciferase imaging in bones other than long bones following 
OVX may be due to tumour cells not being disseminated in these sites, this may also be true 
for lack of tumour growth in soft tissues observed in this model. In the current study only 
tibiae were harvested for two-photon analysis of disseminated tumour cells and therefore, 
dissemination at other sites remains to be confirmed. MDA-MB-231 breast cancer cells are 
oestrogen-independent, whereas the majority of bone metastases occur from oestrogen 
receptor positive tumours. In an attempt to better reflect bone metastasis from human 
breast cancer, we carried out pilot studies of tumour cell dormancy in bone using oestrogen-
dependent MCF7 cells. In the absence of oestrogen supplementation, these cells did not 
form bone metastasis following i.c. injection over the subsequent 20 weeks (data not 
shown). In addition, oestrogen supplementation caused major changes to the bone 
environment and could not be used in conjunction with OVX (8). We have, therefore, 
focused this study on oestrogen-independent cells. 
Our previous data support that stimulation of disseminated tumour cells in bone to 
proliferate and form metastases is likely to be driven by osteoclast-mediated mechanisms 
(8). We have now tested this hypothesis by investigating the effects of inhibiting 
RANK/RANKL interactions on OVX-induced bone metastases. The binding of RANKL to its 
cognate receptor RANK is essential for osteoclast maturation, function and survival. The 
presence of tumour cells in the bone environment stimulates production of RANKL from 
osteoblasts:  In vitro co-culture of MDA-MB-231 cells with the human osteoblast cell line 
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MG-63 results in enhanced production of RANKL (22). Furthermore, MDA-MB-231 cells that 
do not express RANKL when cultured alone, demonstrate increased RANKL mRNA expression 
when co-cultured with primary osteoblasts or ST2 osteoblastic cells (23). This increase in 
RANKL from tumour cells and osteoblasts have the potential to stimulate osteoclastogenesis 
and drive the formation of osteolytic lesions. Disrupting this interaction via administration of 
pharmacological RANKL inhibitors including such as RANKL-Fc and OPG-Fc have been show 
to prevent tumour-associated bone destruction and reduce tumour growth in bone from a 
variety of tumours including breast, lung, prostate, renal and colon (reviewed in 24). In 
addition, giving OPG, either simultaneously with or before, tumour cell injection 
demonstrated that RANKL inhibition significantly delayed de novo formation of MDA-MB-
231 breast cancer skeletal metastases (25). Pre-clinical studies show impressive anti-bone 
metastases effects with RANKL inhibitors and have led to the development of a fully human 
monoclonal antibody to RANKL (Denosumab) that is currently undergoing a number of 
clinical trials as a treatment for cancer induced bone disease and to increase bone 
metastasis-free survival (reviewed in 26 and 27). However, none of the pre-clinical studies 
have addressed the important clinical question of whether inhibiting RANKL has any effect 
on dormant tumour cells in the bone microenvironment.  
The majority of women who develop bone metastases are post-menopausal and recently 
published data from clinical trials have shown that treating patients at high risk of 
developing bone metastases with zoledronic acid is only beneficial to patients who are 5-
years or more post-menopausal (28). These data indicate that inhibition of osteoclast 
activity may have specific anti-tumour effects in a low oestrogen environment. In the 
current study we mimic the post-menopausal low oestrogen environment by OVX. Our 
current data support our previous findings that OVX significantly increases osteoclast activity 
and stimulates proliferation of dormant disseminated tumour cells in bone (8). We now 
show that these processes are completely inhibited following weekly administration of 
25mg/kg OPG-Fc. In vitro co-culture studies with breast cancer (MDA-MB-231, MCF7 or 
T47D) cells and osteoblastic cells indicate that contact with bone can induce expression of 
RANKL by breast cancer cells and therefore it is possible that inhibiting RANKL may have 
direct anti-tumour effects on cancer cells growing in the skeleton (29). These findings may in 
part explain the increased survival benefit seen when treating breast and prostate cancer 
patients with bone metastases with denosumab compared with zoledronic acid (13). 
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OPG-Fc is a pharmacologically enhanced native OPG synthesised by Amgen from which the 
heparin binding domain and the death domain homologous regions have been removed and 
the remaining amino acids 22-194 OPG peptide have been fused to the Fc domain of human 
IgG1 (15). The resulting OPG-Fc is a potent as full length OPG but shows a significantly 
increased circulating half-life. The compound we used is endotoxin free and has been used 
in multiple published in vivo studies (15, 30-36). The doses of OPG-Fc used in animal models 
of bone metastasis varied considerably depending on the cancer type and duration of the 
experiment (33-36). We chose to administer 25mg/kg OPG-Fc once per week, as this dose is 
previously shown to inhibit MDA-MB-231 tumour growth in bone. We confirmed that this 
treatment regime significantly decreased osteoclastic bone resorption in the mice, resulting 
in significantly decreased osteoclast and osteoblast activity and almost complete elimination 
of these cell types on the trabecular and endocortical surfaces of tibiae 4 weeks following 
commencement of treatment. Interestingly, despite decreased activity of osteoblasts, the 
growth tibial growth plates were significantly larger in OPG-Fc treated mice compared with 
control animals, a phenomenon also seen following administration of zoledronic acid (37). 
Safranin O staining revealed that the enlarged growth plates were made up of proteoglycan 
with increased numbers of chondrocytes, indicating that inhibition of osteoclast activity is 
modifying endochondral ossification in this model. However, as the primary goal of this 
study was to investigate the effects on inhibiting RANK-RANKL interactions on tumour 
growth in bone, the effects of OPG-Fc on chondrocytes will be the subject of separate 
investigations. 
In conclusion, our study presents the first data showing that disruption of RANK-RANKL 
interactions following administration of OPG-Fc inhibits growth of dormant tumour cells 
disseminated in bone in vivo. Our data support early intervention with anti-resorptive 
therapy in a low-oestrogen environment to prevent development of bone metastases. 
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Figure legends 
Figure 1. Effects of ovariectomy on proliferation of MDA-MB-231 breast cancer cells in 
bone following long-term dormancy. Panel a) is a diagrammatic representation of the 
protocol. Panel b) presents photographs of luciferase expressing MDA-MB-231 cells growing 
in female BALB/c nude mice 84 days following tumour cell injection and 28 days following 
ovariectomy or sham operation. Percentage of mice with tumours growing in bone and soft 
tissue on day 56 (at ovariectomy) and after ovariectomy are show in in panel c. Panel d 
shows dormant MDA-MB-231 cells in mouse tibia 56 days after tumour cell injection and 
panel e shows the effect of ovariectomy on bone volume 28 days following operation. 
 
Figure 2. Effects of OPG-Fc on mouse long bone. Female BALB/c nude mice were treated 
with 25mg/kg OPG-Fc or 0.1ml of 0.2% saline 1x per week for 4 weeks, panel a) shows 
histological sections following Goldner’s staining (bone shown in green), Safranin O staining 
(non-ossified bone shown in red) and TRAP staining (osteoclasts can be identified as large, 
pink, multinucleated cells lining the bone surface and osteoblasts are highlighted with black 
arrows). μCT images showing bone architecture are shown in panel b) and panel c) is a graph 
showing the effects of OPG-Fc on bone volume compared with trabecular volume ± SEM. 
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ELISA analysis of serum TRAP (units per litre) and P1NP (ng/ml) ± SEM are shown in panels d) 
and e) respectively. * = p<0.01, *** = p<0.0001. 
Figure 3. Effects of OPG-Fc on growth of MDA-MB-231 tumour cells in vitro. Line graphs 
showing effects of increasing concentration of OPG-Fc on growth of MDA-MB-231 tumour 
cells in media supplemented with 10% FCS a) and reduced serum concentration on growth 
of MDA-MB-231 tumour cells treated with saline or 100g/ml OPG-Fc b) for up to 6 days in 
culture. Panel c) shows effects of increasing concentrations of OPG-Fc on ability of MDA-MB-
231 cells to form colonies on plastic. Data presented as mean ± SEM. 
 
Figure 4. Effects of OPG-Fc on ovariectomy-induced tumour growth in bone. Panel a) is a 
diagrammatic representation of the experimental protocol. Panel b) presents photographs 
of luciferase expressing MDA-MB-231 cells growing in female BALB/c nude mice 31 days 
following injection of saline or OPG-Fc and 28 days following ovariectomy or sham operation. 
Panel c) shows the percentage of mice with tumours in bone and outside of bone (lungs and 
eye socket) at the end of the experiment and panel d) shows mean bioluminescence per 
tumour in bone and outside of bone ± SEM. *** = p<0.0001. Panel e) shows 
photomicrographs of H&E stained histological sections from the left tibiae of BALB/c nude 
mice 31 day following injection of saline or OPG-Fc and 28 days following ovariectomy or 
sham operation, tumour circumference in bone is highlighted in blue. 
Figure 5. Effects of OPG-Fc on ovariectomy-induced bone loss in the tibia. Panel a) shows 
cross sectional and longitudinal images of female BALB/c mouse tibiae following 4 weekly 
injections of saline (control) or 25mg/kg OPG-Fc and 28 days following either sham 
operation or ovariectomy. Panel b) shows trabecular volume compared with bone volume 
for these mice and panels c) and d) show ELISA analysis of serum TRAP (units per litre) and 
P1NP (ng/ml) ± SEM respectively. *** = P < 0.0001 
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